$DXR

DAXOR CORP

Daxor is a medical instrumentation and biotechnology company based in Oak Ridge, Tennessee. Its products include the BVA-100, a device for measuring blood volume in people, and Volumex, a disposable radiopharmaceutical kit for diagnostic injection and sample collection.

No enriched coverage for $DXR in the last 7 days.

No SEC Form 4 filings for $DXR in the last 30 days.

See all $DXR insider activity →
Low

Daxor Corporation Launches BVA Program at Kansas Medical Center

Daxor Corporation expanded its blood volume analysis program to a Kansas medical center, offering 24-hour turnaround via its Tennessee-based lab. The company reported no upfront costs or onsite lab requirements. No financial results or adoption metrics were disclosed.

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

Daxor Corporation (DXR) will showcase its FDA-cleared next-gen Blood Volume Analyzer (BVA) at HFSA 2026, featuring 3x faster results and 50% less blood required. Clinical data on heart failure management will be presented, highlighting BVA's accuracy and efficiency. The event runs Oct 9-12, 2026, in Phoenix, AZ.

DXR sentiment & insider activity

Recent DXR coverage spans financial news, technology and corporate actions.

What's driving DXR

  • Daxor Corporation expanded its blood volume analysis program to a Kansas medical center, offering 24-hour turnaround via its Tennessee-based lab. The company reported no upfront costs or onsite lab requirements. No financial results or adoption metrics were disclosed.

    tradingview.com · Nov 17, 2026

  • Positive trial data suggests broader adoption of BVA, likely boosting Daxor's revenue outlook.

    investing.com · Oct 14, 2026

  • The product launch may modestly improve Daxor's market visibility and future sales pipeline, but no immediate financial impact is disclosed.

    globenewswire.com · Oct 1, 2026

  • The filing is a routine corporate governance update; it does not disclose new financial guidance, deals, or regulatory outcomes.

    SEC EDGAR 8-K · Jun 24, 2026

  • Patent issuance strengthens DXR’s IP moat and supports commercialization of remote, continuous blood-volume monitoring for chronic conditions.

    manilatimes.net · Jun 2, 2026

AlphAI scores every news story that mentions DXR with an AI model for sentiment and relevance, and aggregates insider trades from DAXOR CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DXR

Score
$DXRMedAI 8/10

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

$DXRLowShareholder vote

DAXOR CORP (DXR): Submission of Matters to a Vote of Security Holders

DAXOR CORP (DXR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000027367 0000027367 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

$DXRMedAI 8/10

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

Daxor Signs Multiple Material Agreements

Daxor (DXR) has entered into two significant agreements to support a registered direct equity offering. The company signed a Securities Purchase Agreement with investors to sell 765,958 common shares at $11.75 per share, resulting in approximately $8.14 million in net proceeds. Additionally, Daxor signed a Placement Agency Agreement with Lake Street Capital Markets, which facilitated the transaction that closed on January 26, 2026, with proceeds earmarked for general corporate and growth needs.

Related tickers